Harnessing the Microbiome: Unveiling the Influence of the Gut Microbiota on Hepatobiliary Cancer Therapeutic Strategies [0.03%]
调控微生物群：揭示肠道菌群对肝胆道癌症治疗策略的影响
Melody Yusong Li,Xue Qian Wu,Terence Kin Wah Lee
Melody Yusong Li
The gut microbiota significantly influences hepatobiliary cancer therapeutics. Growing evidence indicates that shifts in the gut microbial ecosystem are hallmarks of hepatocellular carcinoma and cholangiocarcinoma, strongly correlating with...
Genome-wide SNP-BMI interaction analysis highlights CYP7A1 and GIPR as two novel genetic modifiers of MASLD [0.03%]
全基因组SNP-BMI相互作用分析揭示了CYP7A1和GIPR是两种新的MASLD遗传修饰因子
Julia Kozlitina
Julia Kozlitina
Plasma Lipidomic and Fungal Signatures Predict Early Mortality in Acute Liver Failure [0.03%]
血浆脂质组学和真菌标志物可预测急性肝功能衰竭患者的早期死亡率
Yu Ji Kim,Jong-Won Kim
Yu Ji Kim
Tumor-based biomarkers and circulating tumor DNA for precision medicine in advanced hepatocellular carcinoma [0.03%]
基于肿瘤的生物标志物和循环肿瘤DNA在晚期肝细胞癌精确医学中的作用
Sabrina Sidali,Claudia Campani,Jihyun An et al.
Sabrina Sidali et al.
Hepatocellular carcinoma (HCC) is the most common primary liver cancer and remains a major cause of cancer-related mortality worldwide. Systemic therapies, including targeted therapies and immune checkpoint inhibitors (ICIs), have revolutio...
Letter "GLP-1 RA and Reduced Liver and Non-Liver Complications in Adults with T2D and MASLD: A Target Trial Emulation Study" [0.03%]
GLP-1受体激动剂可降低T2DM合并非肝硬化门静脉高压患者各种结局的风险：靶向试验模拟研究
Chunyan Wang,Xu Han,Yinyan Li
Chunyan Wang
Reply to correspondence on "Factors associated with hepatitis B mother-to-child transmission in a national prevention program" [0.03%]
关于“全国孕产妇乙肝母婴阻断项目中与乙肝母婴传播相关因素”来信的回复
Eunho Choi,Ji Hoon Kim,Young-Sun Lee
Eunho Choi